Navigating New Horizons: Prospects of NET-targeted Radiopharmaceuticals in Precision Medicine

Overview

Journal Theranostics

Date 2024 Jun 10

PMID 38855189

Authors

Takahiro Higuchi

Xinyu Chen

Rudolf A Werner

Affiliations

Soon will be listed here.

Abstract

In the evolving landscape of precision medicine, NET-targeted radiopharmaceuticals are emerging as pivotal tools for the diagnosis and treatment of a range of conditions, from heart failure and neurodegenerative disorders to neuroendocrine cancers. This review evaluates the advancements offered by F-labeled PET tracers and At alpha-particle therapy, juxtaposed with current I-MIBG SPECT and I-MIBG therapies. The enhanced spatial resolution and capability for quantitative analysis render F-labeled PET tracers potential candidates for improved detection and management of diseases. Alpha-particle therapy with At may offer increased specificity and tumoricidal efficacy, pointing towards a shift in therapeutic protocols. While preliminary data is promising, these innovative approaches require thorough validation against current modalities. Ongoing clinical trials are pivotal to confirm the expected clinical benefits and to address safety concerns. This review underscores the need for rigorous research to verify the clinical utility of NET-targeted radiopharmaceuticals, which may redefine precision medicine paradigms and significantly impact patient care.

Citing Articles

Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211.

Kaneda-Nakashima K, Shirakami Y, Hisada K, Feng S, Kadonaga Y, Ooe K Int J Mol Sci. 2024; 25(22).

PMID: 39596451 PMC: 11594329. DOI: 10.3390/ijms252212386.

References

Pfeiffer R . Autonomic Dysfunction in Parkinson's Disease. Neurotherapeutics. 2020; 17(4):1464-1479. PMC: 7851208. DOI: 10.1007/s13311-020-00897-4. View

Hellwig D, Hellwig N, Boehner S, Fuchs T, Fischer R, Schmidt D . Artificial Intelligence and Deep Learning for Advancing PET Image Reconstruction: State-of-the-Art and Future Directions. Nuklearmedizin. 2023; 62(6):334-342. PMC: 10689088. DOI: 10.1055/a-2198-0358. View

Jang K, Jung Y, Gu G, Koeppe R, Sherman P, Quesada C . 4-[18F]Fluoro-m-hydroxyphenethylguanidine: a radiopharmaceutical for quantifying regional cardiac sympathetic nerve density with positron emission tomography. J Med Chem. 2013; 56(18):7312-23. PMC: 4520396. DOI: 10.1021/jm400770g. View

Grkovski M, Zanzonico P, Modak S, Humm J, Narula J, Pandit-Taskar N . F-18 meta-fluorobenzylguanidine PET imaging of myocardial sympathetic innervation. J Nucl Cardiol. 2022; 29(6):3179-3188. PMC: 10155237. DOI: 10.1007/s12350-021-02813-5. View

HOLMAN B, Tumeh S . Single-photon emission computed tomography (SPECT). Applications and potential. JAMA. 1990; 263(4):561-4. View

Madsen M, Bushnell D, Juweid M, Menda Y, ODorisio M, ODorisio T . Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. J Nucl Med. 2006; 47(4):660-7. View

Fallavollita J, Heavey B, Luisi Jr A, Michalek S, Baldwa S, Mashtare Jr T . Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2013; 63(2):141-9. PMC: 3954563. DOI: 10.1016/j.jacc.2013.07.096. View

Rabiei M, Asadi M, Yousefnia H . Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future. Curr Radiopharm. 2023; 17(1):7-13. DOI: 10.2174/0118744710262325231025075638. View

Shulkin B, Wieland D, Baro M, Ungar D, Mitchell D, Dole M . PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med. 1996; 37(1):16-21. View

10.

Werner R, Kobayashi R, Javadi M, Kock Z, Wakabayashi H, Unterecker S . Impact of Novel Antidepressants on Cardiac I-Metaiodobenzylguanidine Uptake: Experimental Studies on SK-N-SH Cells and Healthy Rabbits. J Nucl Med. 2018; 59(7):1099-1103. DOI: 10.2967/jnumed.117.206045. View

11.

Tutov A, Chen X, Werner R, Muhlig S, Zimmermann T, Nose N . Rationalizing the Binding Modes of PET Radiotracers Targeting the Norepinephrine Transporter. Pharmaceutics. 2023; 15(2). PMC: 9963373. DOI: 10.3390/pharmaceutics15020690. View

12.

Hoefnagel C, de Kraker J, Valdes Olmos R, VOUTE P . 131I-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl Med Commun. 1994; 15(9):712-7. DOI: 10.1097/00006231-199409000-00008. View

13.

Gonzalez-Montoro A, Ullah M, Levin C . Advances in Detector Instrumentation for PET. J Nucl Med. 2022; 63(8):1138-1144. PMC: 9364348. DOI: 10.2967/jnumed.121.262509. View

14.

Weiss B, Yanik G, Naranjo A, Zhang F, Fitzgerald W, Shulkin B . A safety and feasibility trial of I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. Pediatr Blood Cancer. 2021; 68(10):e29117. PMC: 9150928. DOI: 10.1002/pbc.29117. View

15.

Werner R, Rischpler C, Onthank D, Lapa C, Robinson S, Samnick S . Retention Kinetics of the 18F-Labeled Sympathetic Nerve PET Tracer LMI1195: Comparison with 11C-Hydroxyephedrine and 123I-MIBG. J Nucl Med. 2015; 56(9):1429-33. DOI: 10.2967/jnumed.115.158493. View

16.

Huang S, Savic D, Yang J, Shrestha U, Seo Y . The Effect of Magnetic Field on Positron Range and Spatial Resolution in an Integrated Whole-Body Time-Of-Flight PET/MRI System. IEEE Nucl Sci Symp Conf Rec (1997). 2016; 2014. PMC: 4828037. DOI: 10.1109/NSSMIC.2014.7431006. View

17.

Rissardo J, Caprara A . Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson's Disease: A Comprehensive Review. Brain Sci. 2023; 13(10). PMC: 10605004. DOI: 10.3390/brainsci13101471. View

18.

Nakajima K, Nakata T . Cardiac 123I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan. J Nucl Med. 2015; 56 Suppl 4:11S-19S. DOI: 10.2967/jnumed.114.142794. View

19.

Kantorovich V, Pacak K . Pheochromocytoma and paraganglioma. Prog Brain Res. 2010; 182:343-73. PMC: 4714594. DOI: 10.1016/S0079-6123(10)82015-1. View

20.

Jacobson A, Senior R, Cerqueira M, Wong N, Thomas G, Lopez V . Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010; 55(20):2212-21. DOI: 10.1016/j.jacc.2010.01.014. View